CN103735727A - Traditional Chinese medicine for treating amblyopia and preparation method thereof - Google Patents
Traditional Chinese medicine for treating amblyopia and preparation method thereof Download PDFInfo
- Publication number
- CN103735727A CN103735727A CN201310382306.3A CN201310382306A CN103735727A CN 103735727 A CN103735727 A CN 103735727A CN 201310382306 A CN201310382306 A CN 201310382306A CN 103735727 A CN103735727 A CN 103735727A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- amblyopia
- chinese medicine
- radix
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine for treating amblyopia and a preparation method thereof, comprising the following components by weight: 5-20 parts of wolfberry, 2-25 parts of prepared rehmannia root, 5-20 parts of Chinese angelica, 5-20 parts of white peony root, 2-15 parts of radix astragali, 2-15 parts of semen cuscutae, 1-10 parts of phellodendron, and 1-10 parts of radix bupleuri. The traditional Chinese medicine solves the problems of poor amblyopia treatment effect and eyesight rollback after stopping treatment in the prior art.
Description
Technical field
The present invention relates to technical field of Chinese medicines, refer to especially a kind of Chinese medicine for the treatment of amblyopia and preparation method thereof.
Background technology
Amblyopia is the common eye diseases in children of clinical ophthalmology, and being that a kind of simple eye or eyes are best corrects defects of vision lower than normally, and fails to find the eyeball organic change corresponding with this visual deterioration.Its Clinical symptoms be eye without significant organic pathological changes, take functional factor as main visual deterioration, and can not adopt frame eyeglasses to correct, amblyopia is mainly central vision defect, grievous injury children ' s vision, therefore, prevent and treat amblyopia significant.
According to epidemiology statistics in 1985, Chinese children amblyopia rate was 2.86%, and data differences is little therewith for the amblyopia rate of many reports in recent years, and as the eye diseases in children investigation of 5000 of Beijing suburb is shown, amblyopia prevalence is 3.21%; 10317 of Shandong Province child is carried out to the ill investigation of amblyopia, and amblyopia prevalence is 3.121%.The modal paathogenic factor of amblyopia is weakening of the visual quality that causes of stravismus, ametropia or ocular media opacity.Neuro physiology mechanism and the binocular rivalry of its generation suppress to have substantial connection.The treatment of amblyopia is focus and the difficulties in ophthalmology research always, generally acknowledged Therapeutic Principle must eliminate shape feel to stimulate blocking-up within visual development sensitive period at present, adjust abnormal binocular interaction, recover binocular visual function, otherwise visual function abnormal development is by irreversible.But owing to now the formation of stereoscopic vision also not being made clear period completely, although therefore the treatment of amblyopia gets along with, at present still without best effectively therapeutic scheme.
The subject matter existing in the treatment of amblyopia has:
1. therapeutic effect is dissatisfied.The factor that affects amblyopia treating effect is a lot, all can cause the dissatisfied of therapeutic effect with age of onset, treatment time, amblyopia type, degree and Therapeutic Method, the accuracy of correction of refractive errors, patient's compliance etc.
2. stop the vision rollback after treatment.
3. novel method for the treatment of uncertain therapeutic efficacy is fixed.The therapeutic effect of many novel medicines or novel therapeutic equipments or method (as vision enhancer, visual function therapeutic instrument, depending on irritation therapy, light brush therapy etc.) is difficult to objective evaluation, clinical use is not yet promoted, and its therapeutic effect still lacks further confirmation.
Traditional medicine think amblyopia be with eye without significant organic pathological changes, take functional factor as main caused distant vision lower than 0.8 and can not correct the general name of oculopathy.Due to historical reason, the traditional Chinese medical science there is no the clear and definite title about amblyopia so far, because of amblyopia how relevant with the factor of hypermetropia, myopia, astigmatism, stravismus and other influences visual development, in document, forefathers are summed up in the point that in oculopathy as relevant in " blurring of vission ", " optic atrohic blindness ", " poor vision " etc. in ancient times.To pathogenetic understanding also corresponding being embodied in " can near timid far away ", " can be far away timid near ", " esotropia in children " and " children's look unfamiliar nebula " that can cause amblyopia.Amblyopia be natural endowment deficiency, conserve one's health inappropriate the day after tomorrow, kidney qi is not filled, and causes Liver and kidney deficiency of YIN-essence, tasteization are raw not enough, QI and blood seminal fluid can not on hold in order, loss of nutrient of eyes, God Light occurs passive, with the passing of time becomes amblyopia.Be that amblyopia is the oculopathy take visual development obstacle as feature, cause of disease complexity, but natural endowment deficiency, lose and support the day after tomorrow, take good care of oneself inappropriate, and precise and tiny QI-blood failing to nourish upward, it is its main pathomechanism that God Light occurs passive.The first duty of internal organs in Liver and kidney dysfunction of spleen and stomach.
Summary of the invention
The present invention proposes a kind of Chinese medicine for the treatment of amblyopia, solved the problem that amblyopia treating effect in prior art is not good, stop the vision rollback after treatment.
Technical scheme of the present invention is achieved in that a kind of Chinese medicine for the treatment of amblyopia, comprises the component of following weight portion:
Fructus Lycii 5～20 weight portions, Radix Rehmanniae Preparata 5～25 weight portions, Radix Angelicae Sinensis 5～20 weight portions, the Radix Paeoniae Alba 5～20 weight portions, the Radix Astragali 2～15 weight portions, Semen Cuscutae 2～15 weight portions, Cortex Phellodendri 1～10 weight portion, Radix Bupleuri 1～10 weight portion.
As preferred technical scheme, treat a Chinese medicine for amblyopia, comprise the component of following weight portion: Fructus Lycii 10～20 weight portions, Radix Rehmanniae Preparata 10～20 weight portions, Radix Angelicae Sinensis 10～20 weight portions, the Radix Paeoniae Alba 10～20 weight portions, the Radix Astragali 2～10 weight portions, Semen Cuscutae 2～10 weight portions, Cortex Phellodendri 2～10 weight portions, Radix Bupleuri 2～10 weight portions.
As preferred technical scheme, treat a Chinese medicine for amblyopia, comprise the component of following weight portion: Fructus Lycii 15 weight portions, Radix Rehmanniae Preparata 20 weight portions, Radix Angelicae Sinensis 15 weight portions, the Radix Paeoniae Alba 15 weight portions, the Radix Astragali 6 weight portions, Semen Cuscutae 6 weight portions, Cortex Phellodendri 4 weight portions, Radix Bupleuri 2 weight portions.
As preferred technical scheme, treat a Chinese medicine for amblyopia, also comprise a kind of or several arbitrarily in diluent, absorbent, wetting agent, binding agent, disintegrating agent, lubricant, suspending agent, flocculating agent, deflocculant, sweeting agent, aromatic, flavoring agent, stabilizing agent or antiseptic.
Described diluent and absorbent can be one or more in starch, dextrin, Icing Sugar, lactose, calcium sulfate, calcium hydrogen phosphate, magnesium oxide, magnesium carbonate, calcium carbonate, aluminium hydroxide, mannitol, sorbitol.
Described wetting agent and binding agent can be one or more in water, ethanol, starch slurry, syrup, maltose, refined honey, liquid glucose, mucialga of arabic gummy, gelatine size, methylcellulose, carboxymethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, polyvidone.
Described disintegrating agent can be one or more in starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, sodium carbonate, citric acid, tartaric acid, tween 80, sodium lauryl sulphate.
Described lubricant can be one or more in stearic acid, calcium stearate, magnesium stearate, Pulvis Talci, hydrogenated vegetable oil, Macrogol 4000, polyethylene glycol 6000, Stepanol MG, micropowder silica gel.
Described suspending agent can be one or more in glycerol, syrup, arabic gum, tragacanth, agar, sodium alginate, Rhizoma Bletillae gel, pectin, methylcellulose, hydroxyethyl-cellulose, hydroxypropyl emthylcellulose, polyvidone, polyvinyl alcohol, silicon dioxide, kieselguhr, aluminium silicate.
Flocculating agent and deflocculant can be one or more in citrate, citric acid hydrogen salt, biatrate, phosphate, chlorate.
Described sweeting agent can be one or more in sucrose, lactose, maltose, glucose, fructose, xylitol, mannitol sugar, sorbitol, glycerol, glycyrrhizic glycoside, stevioside, saccharin sodium, glycine, aspartoyl benzene, alanine.
Described aromatic can be one or more in Oleum menthae, menthol, orange peel oil, aqua cinnamomi, citric acid, flavoring banana essence, flavoring pineapple essence.
Described flavoring agent can be one or more in sodium chloride, saccharin sodium, sweetener, cyclamate, acesulfame potassium, oligofructose, Momordia grosvenori aglycone sugar, sodium glutamate, citric acid, tartaric acid, malic acid, lactic acid, acetic acid.
Described stabilizing agent can be one or more in sodium sulfite, sodium sulfite, pyrosulfurous acid hydrogen sodium, sodium thiosulfate, vitamin C, thiourea, ascorbyl stearate, dibutyl hydroxy toluene, cysteine, tocopherol acetas, dichloro isocyanide, disodiumedetate, calcio-disodium edetate, dimercaptopropanol, BAL, glycerol, mannitol.
Described antiseptic can be one or more in ethyl hydroxybenzoate, methyl hydroxybenzoate, propylparaben, benzalkonium chloride, benzalkonium bromide, chlorobutanol, benzylalcohol, phenethanol, phenol, cresol, sorbic acid.
Described medicine type is tablet, capsule, powder, capsule, granule, watered pill, honey pill agent, concentrated pill, drop pill, oral administration solution, suspensoid, Emulsion, drop, medicated wine or tincture.
Technical solution of the present invention is pathogenetic understanding and the Therapeutic Principle to amblyopia based on the traditional Chinese medical science, with reference to pharmacology of Chinese materia medica, the Chinese medicine with effects such as gas, invigorating the spleen and replenishing QI, invigorating the spleen and regulating the stomach, strengthening the body resistance, replenishing vital essence to improve eyesights in spleen invigorating improving eyesight, nourishing liver, invigorating kidney, tonification liver blood, nourishing blood to suppress the hyperactive liver improving eyesight, spleen reinforcing nourishing the stomach, strong fortune filtering out from Chinese herbal medicine, according to the tcm prescription principles of formulating prescriptions " monarch, minister, help, make " compatibility, form, thereby reach the object for the treatment of amblyopia.
Traditional Chinese medicine compound composition liver and kidney tonifying of the present invention, spleen benefiting and replenishing qi and blood is Therapeutic Principle, mainly by Fructus Lycii, Radix Rehmanniae Preparata, Radix Angelicae Sinensis, the Radix Paeoniae Alba, the Radix Astragali, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri etc.
We select liver and kidney tonifying, benefiting essence-blood, and the Fructus Lycii of spleen invigorating improving eyesight and Radix Rehmanniae Preparata are monarch drug.Fructus Lycii nourishing the liver and kidney, nourishing the liver to improve visual acuity, Radix Rehmanniae Preparata nourishing liver, invigorating kidney, essence and blood is also mended, and kind nourishing kidney consolidates, and mends congenital deficiency, share with Fructus Lycii, plays altogether nourishing the liver and kidney, the effect of replenishing essence improving eyesight.Radix Angelicae Sinensis, the Radix Paeoniae Alba is ministerial drug.When being included into liver spleen heart channel, can tonifying liver blood and improving eyesight, mend and can manage it.The Radix Paeoniae Alba returns Liver and kidney warp, tonification liver blood, nourishing blood to suppress the hyperactive liver improving eyesight, the person that is specially adapted to deficiency of liver-blood.Share sour and sweet drugs can transforme into YIN with Radix Angelicae Sinensis compatibility, liver is hidden to some extent, and normal vision relying on sufficiency of liver-blood makes to reach in order on the blood in liver, plays altogether the merit of nourishing blood for improving eyesight.The Radix Astragali, Semen Cuscutae is adjuvant drug, and Radix Astragali benefiting QI for strengthening the superficies, arresting sweating are admittedly de-, are QI invigorating good merchantable brand, can rise and can fall, and the yang aspect of yang also, can help the merit of Radix Angelicae Sinensis, Radix Paeoniae Alba nourishing blood to promote the production of body fluid.Semen Cuscutae the kidney invigorating and essence nourishing, nourishing the liver to improve visual acuity strengthening the spleen, not only can YANG invigorating but also can tonifying YIN, with Radix Rehmanniae Preparata with there being the effect of enhancing nourishing the liver to improve visual acuity.Cortex Phellodendri, Radix Bupleuri is for making medicine.The sedimentation of Cortex Phellodendri bitter cold, makes fire go not impairment of YIN again, can prevent from tonic, causing for a long time hyperactivity of fire impairment of YIN, Radix Bupleuri removing nebula to improve visual acuity, and elevate a turnable ladder yang-energy, can help its function of improving eyesight with Fructus Lycii, Radix Rehmanniae Preparata compatibility, and another Radix Bupleuri can draw the through eye of all medicines, improves the drug effect of perfect square.
The medication feature of full side is that medicine is concentrated and returned through in liver spleen kidney, the nature and nurture people having the same aspiration and interest, and medicine unbiasedness, a medicine multiple-effect, grows and oiliness, and sound is suitable, regulating YIN and YANG.Both the physiological characteristics of having considered eye, has extremely strong specific aim to child again.Clinical efficacy is remarkable, adopts modern crafts to be prepared into different dosage forms simultaneously, has kept decoct drug effect high, absorb soon, and the advantage rapidly of proving effective, and overcome decoction decoction inconvenience, the drawback that consumption is bigger than normal.
The present invention also proposes a kind of method of preparing the Chinese medicine for the treatment of amblyopia, comprises step:
1) get that the Radix Rehmanniae Preparata of Fructus Lycii, 5～25 amounts part of 5～20 weight portions is heavy, the Radix Angelicae Sinensis of 5～20 weight portions, the Radix Paeoniae Alba of 5～20 weight portions, the Radix Astragali of 2～15 weight portions, the Semen Cuscutae of 2～15 weight portions, the Cortex Phellodendri of 1～10 weight portion, the Radix Bupleuri of 1～10 weight portion;
2) the above-mentioned crude drug taking is added to the water of 5～6 times of weight of described crude drug, at 90～100 ℃, decoct 1.5～2.5h, filter and obtain residue and decocting liquid;
3) above-mentioned residue is added to the water of 5～6 times of weight of described crude drug, at 90～100 ℃, decoct 0.5～1.5h, the decocting liquid that above-mentioned decocting liquid and this decoction are obtained merges;
4) clear paste that is 1～1.3 by the decocting liquid concentrating under reduced pressure after above-mentioned merging to the density with respect to water;
5) to adding mass concentration in above-mentioned clear paste, be 92～98% ethanol, the clear paste alcoholic solution that to obtain containing alcohol amount be 58～62%;
6) by the static 20～24h of above-mentioned clear paste alcoholic solution, get supernatant concentrating under reduced pressure and reclaim ethanol, obtain the Chinese medicine of described treatment amblyopia.
As the improvement to technique scheme, to the water that adds 1～1.2 times of weight of described crude drug in the Chinese medicine of described treatment amblyopia, regulate pH value to 7.1～7.3, stir, standing, filter, subpackage obtains the Chinese medicine oral liquid for the treatment of amblyopia.
As the another improvement to technique scheme, the traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is granulated, be dried, incapsulate and obtain the capsule of the Chinese medicine of described treatment amblyopia.
As another improvement to technique scheme, the traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is made to pill, tablet or the granular preparation of the Chinese medicine of described treatment amblyopia.
As the improvement again to technique scheme, the traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is made to the tablet of the Chinese medicine of described treatment amblyopia.
As the improvement to technique scheme, can also be to adding a kind of or several arbitrarily in diluent, absorbent, wetting agent, binding agent, disintegrating agent, lubricant, suspending agent, flocculating agent, deflocculant, sweeting agent, aromatic, flavoring agent, stabilizing agent or antiseptic in the described Chinese medicine of stating treatment amblyopia.
Described diluent and absorbent can be one or more in starch, dextrin, Icing Sugar, lactose, calcium sulfate, calcium hydrogen phosphate, magnesium oxide, magnesium carbonate, calcium carbonate, aluminium hydroxide, mannitol, sorbitol.
Described wetting agent and binding agent can be one or more in water, ethanol, starch slurry, syrup, maltose, refined honey, liquid glucose, mucialga of arabic gummy, gelatine size, methylcellulose, carboxymethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, polyvidone.
Described disintegrating agent can be one or more in starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, sodium carbonate, citric acid, tartaric acid, tween 80, sodium lauryl sulphate.
Described lubricant can be one or more in stearic acid, calcium stearate, magnesium stearate, Pulvis Talci, hydrogenated vegetable oil, Macrogol 4000, polyethylene glycol 6000, Stepanol MG, micropowder silica gel.
Described suspending agent can be one or more in glycerol, syrup, arabic gum, tragacanth, agar, sodium alginate, Rhizoma Bletillae gel, pectin, methylcellulose, hydroxyethyl-cellulose, hydroxypropyl emthylcellulose, polyvidone, polyvinyl alcohol, silicon dioxide, kieselguhr, aluminium silicate.
Flocculating agent and deflocculant can be one or more in citrate, citric acid hydrogen salt, biatrate, phosphate, chlorate.
Described sweeting agent can be one or more in sucrose, lactose, maltose, glucose, fructose, xylitol, mannitol sugar, sorbitol, glycerol, glycyrrhizic glycoside, stevioside, saccharin sodium, glycine, aspartoyl benzene, alanine.
Described aromatic can be one or more in Oleum menthae, menthol, orange peel oil, aqua cinnamomi, citric acid, flavoring banana essence, flavoring pineapple essence.
Described flavoring agent can be one or more in sodium chloride, saccharin sodium, sweetener, cyclamate, acesulfame potassium, oligofructose, Momordia grosvenori aglycone sugar, sodium glutamate, citric acid, tartaric acid, malic acid, lactic acid, acetic acid.
Described stabilizing agent can be one or more in sodium sulfite, sodium sulfite, pyrosulfurous acid hydrogen sodium, sodium thiosulfate, vitamin C, thiourea, ascorbyl stearate, dibutyl hydroxy toluene, cysteine, tocopherol acetas, dichloro isocyanide, disodiumedetate, calcio-disodium edetate, dimercaptopropanol, BAL, glycerol, mannitol.
Described antiseptic can be one or more in ethyl hydroxybenzoate, methyl hydroxybenzoate, propylparaben, benzalkonium chloride, benzalkonium bromide, chlorobutanol, benzylalcohol, phenethanol, phenol, cresol, sorbic acid.
Described medicine type is tablet, capsule, powder, capsule, granule, watered pill, honey pill agent, concentrated pill, drop pill, oral administration solution, suspensoid, Emulsion, drop, medicated wine or tincture.
The extraction of Fructus Lycii separates, and because its active chemical is polysaccharide, adopts decoction and alcohol sedimentation technique, will precipitate water-soluble after, by sevag method, remove albumen, filter, concentrate, vacuum drying obtains the polyoses extract of Fructus Lycii.
The extraction of the Radix Paeoniae Alba, Radix Angelicae Sinensis, Cortex Phellodendri, Radix Bupleuri separates, and because its active chemical is saponin and glycoside, first adopts alcoholic solution to extract, then removes after lipotropy impurity with petroleum ether, then uses n-butanol extraction, and drying under reduced pressure obtains methods of glycosides.
The extraction of the Radix Astragali separates, and because its active chemical is flavone, adopts water heating extraction, after aqueous solution is concentrated, adds ethanol precipitation, removes the water-solubility impurities such as protein and polysaccharide, and drying under reduced pressure obtains flavonoids.
The extraction of Radix Rehmanniae Preparata, Semen Cuscutae separates, because its active chemical is multiple different chemical composition, therefore after adopting traditional method to decoct with water, concentrate, to retain its active chemical.
The granulation research on standard of granule:
The thin layer of peoniflorin is differentiated: get this product 2g, prepare need testing solution.Separately get peoniflorin reference substance and prepare reference substance solution.According to thin layer chromatography test, take chloroform-methanol-ammonia as developing solvent, launch, take out, dry, spray is with vanillin ethanol solution of sulfuric acid, in test sample chromatograph, with the corresponding position of reference substance chromatograph on, the speckle of aobvious same color.
The thin layer of astragaloside is differentiated: get this product 4g, prepare need testing solution.Separately get astragaloside reference substance, preparation reference substance solution.According to thin layer chromatography test, take lower floor's solution of chloroform-methanol-water as developing solvent, launch, take out, to dry, spray, with ethanol solution of sulfuric acid, is heated to develop the color clear.In test sample chromatograph, with the corresponding position of reference substance chromatograph on, the speckle of aobvious same color.
The thin layer of Radix Rehmanniae is differentiated: get this product 2g, prepare need testing solution.Separately get Radix Rehmanniae control medicinal material 2g, be made in the same way of control medicinal material solution.According to thin layer chromatography test, silica GF254 lamellae, take petroleum ether-ethyl acetate as developing solvent, launches, and takes out, and dries, and puts under ultra-violet lamp and inspects.In test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, the skin dark stain of aobvious same color.
The assay of peoniflorin: with C18 chromatographic column, methanol-0.1% phosphoric acid is mobility, measures peoniflorin at 230nm place.Peoniflorin is good with peak area integrated value linear relationship within the scope of 0.37-3.7 μ g, and average recovery rate is high, and precision is good, sample is good at 24h internal stability, the method is easy, quick, reproducible, and the method for quality control that can be used as the Chinese medicine compound pharmaceutical composition powder in the present invention is fixed.
Usage: oral.
Taboo matters: nothing.
Owing to having adopted technique scheme, a kind of Chinese medicine for the treatment of amblyopia and preparation method thereof, comprises the component of following weight portion: Fructus Lycii 5～20 weight portions, Radix Rehmanniae Preparata 5～25 weight portions, Radix Angelicae Sinensis 5～20 weight portions, the Radix Paeoniae Alba 5～20 weight portions, the Radix Astragali 2～15 weight portions, Semen Cuscutae 2～15 weight portions, Cortex Phellodendri 1～10 weight portion, Radix Bupleuri 1～10 weight portion; Solved the problem that amblyopia treating effect in prior art is not good, stop the vision rollback after treatment.
By the clinical observation to 30 routine amblyopia patients, the oral Si Liba sheet of matched group, treatment group was taken pharmaceutical composition of the present invention after 3 months, treated forward and backward by observation: the change of vision, P-VEP and nature of fixation.Curative effect determinate standard: invalid: vision regresses, constant or only 1 row of raising; Progressive: vision improves 2 row or more than 2 row; Be almost recovered: correct defects of vision be increased to 0.9 or more than; . recovery from illness: follow up a case by regular visits to through 3 years, it is normal that vision still keeps.Find that pharmaceutical composition of the present invention can obviously improve the visual function of light moderate amblyopia, has significant clinical efficacy.
Before and after treatment, compare
Accompanying drawing explanation
In order to be illustrated more clearly in the embodiment of the present invention or technical scheme of the prior art, to the accompanying drawing of required use in embodiment or description of the Prior Art be briefly described below, apparently, accompanying drawing in the following describes is only some embodiments of the present invention, for those of ordinary skills, do not paying under the prerequisite of creative work, can also obtain according to these accompanying drawings other accompanying drawing.
Fig. 1 is preparation method schematic flow sheet of the present invention;
The specific embodiment
Below in conjunction with the accompanying drawing in the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, obviously, described embodiment is only the present invention's part embodiment, rather than whole embodiment.Based on the embodiment in the present invention, those of ordinary skills, not making the every other embodiment obtaining under creative work prerequisite, belong to the scope of protection of the invention.
Treat as shown in Figure 1 a Chinese medicine for amblyopia, comprise the component of following weight portion:
Treat a Chinese medicine for amblyopia, comprise the component of following weight portion: Fructus Lycii 10～20 weight portions, Radix Rehmanniae Preparata 10～20 weight portions, Radix Angelicae Sinensis 10～20 weight portions, the Radix Paeoniae Alba 10～20 weight portions, the Radix Astragali 2～10 weight portions, Semen Cuscutae 2～10 weight portions, Cortex Phellodendri 2～10 weight portions, Radix Bupleuri 2～10 weight portions.
Treat a Chinese medicine for amblyopia, comprise the component of following weight portion: Fructus Lycii 15 weight portions, Radix Rehmanniae Preparata 20 weight portions, Radix Angelicae Sinensis 15 weight portions, the Radix Paeoniae Alba 15 weight portions, the Radix Astragali 6 weight portions, Semen Cuscutae 6 weight portions, Cortex Phellodendri 4 weight portions, Radix Bupleuri 2 weight portions.
Treat a Chinese medicine for amblyopia, also comprise a kind of or several arbitrarily in diluent, absorbent, wetting agent, binding agent, disintegrating agent, lubricant, suspending agent, flocculating agent, deflocculant, sweeting agent, aromatic, flavoring agent, stabilizing agent or antiseptic.
A method of preparing the Chinese medicine for the treatment of amblyopia, comprises step:
1) get that the Radix Rehmanniae Preparata of Fructus Lycii, 5～25 amounts part of 5～20 weight portions is heavy, the Radix Angelicae Sinensis of 5～20 weight portions, the Radix Paeoniae Alba of 5～20 weight portions, the Radix Astragali of 2～15 weight portions, the Semen Cuscutae of 2～15 weight portions, the Cortex Phellodendri of 1～10 weight portion, the Radix Bupleuri of 1～10 weight portion;
2) the above-mentioned crude drug taking is added to the water of 5～6 times of weight of described crude drug, at 90～100 ℃, decoct 1.5～2.5h, filter and obtain residue and decocting liquid;
3) above-mentioned residue is added to the water of 5～6 times of weight of described crude drug, at 90～100 ℃, decoct 0.5～1.5h, the decocting liquid that above-mentioned decocting liquid and this decoction are obtained merges;
4) clear paste that is 1～1.3 by the decocting liquid concentrating under reduced pressure after above-mentioned merging to the density with respect to water;
5) to adding mass concentration in above-mentioned clear paste, be 92～98% ethanol, the clear paste alcoholic solution that to obtain containing alcohol amount be 58～62%;
6) by the static 20～24h of above-mentioned clear paste alcoholic solution, get supernatant concentrating under reduced pressure and reclaim ethanol, obtain the Chinese medicine of described treatment amblyopia.
To the water that adds 1～1.2 times of weight of described crude drug in the Chinese medicine of described treatment amblyopia, regulate pH value to 7.1～7.3, stir, standing, filter, subpackage obtains the Chinese medicine oral liquid for the treatment of amblyopia.
The traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is granulated, be dried, incapsulate and obtain the capsule of the Chinese medicine of described treatment amblyopia.
The traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is made to pill, tablet or the granular preparation of the Chinese medicine of described treatment amblyopia.
The traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is made to the tablet of the Chinese medicine of described treatment amblyopia.
Can also be to adding a kind of or several arbitrarily in diluent, absorbent, wetting agent, binding agent, disintegrating agent, lubricant, suspending agent, flocculating agent, deflocculant, sweeting agent, aromatic, flavoring agent, stabilizing agent or antiseptic in the described Chinese medicine of stating treatment amblyopia.
Embodiment 1
Fructus Lycii 150g, Radix Rehmanniae Preparata 200g, Radix Angelicae Sinensis 150g, Radix Paeoniae Alba 150g, Radix Astragali 60g, Semen Cuscutae 60g, Cortex Phellodendri 40g, Radix Bupleuri 20g, correctives 5g, antiseptic 2g, finally makes the oral liquid of total amount 1000ml.
Take above-mentioned Fructus Lycii, Radix Rehmanniae Preparata, served as, the Radix Paeoniae Alba, the Radix Astragali, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, add 5000mL water, heating decocts 2h, filters, residue adds 5000mL water, and heating decocts 1h, collecting decoction, under reduced pressure, be concentrated to density and be 1.15 clear paste, add 95% ethanol, make to reach 60% containing alcohol amount, hold over night, gets supernatant, and concentrating under reduced pressure reclaims ethanol, add correctives and antiseptic and add water to 1000ml, regulating pH value to 7.2, stirring evenly, standing, filter subpackage.
Fructus Lycii 150g, Radix Rehmanniae Preparata 200g, Radix Angelicae Sinensis 150g, Radix Paeoniae Alba 150g, Radix Astragali 60g, Semen Cuscutae 60g, Cortex Phellodendri 40g, Radix Bupleuri 20g, lactose is appropriate.
Take above-mentioned Fructus Lycii, Radix Rehmanniae Preparata, served as, the Radix Paeoniae Alba, the Radix Astragali, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, add 5000mL water, heating decocts 2h, filter, residue adds 5000mL water, and heating decocts 1h, collecting decoction, under reduced pressure, be concentrated to density and be 1.15 clear paste, add 95% ethanol, make to reach 60%, hold over night containing alcohol amount, get supernatant, concentrating under reduced pressure reclaims ethanol, is concentrated into thick paste, adds appropriate amount of auxiliary materials, mix homogeneously, granulate, dry, incapsulate, make 1000 of capsules, every heavy 0.3g.
Fructus Lycii 150g, Radix Rehmanniae Preparata 200g, Radix Angelicae Sinensis 150g, Radix Paeoniae Alba 150g, Radix Astragali 60g, Semen Cuscutae 60g, Cortex Phellodendri 40g, Radix Bupleuri 20g.
Take above-mentioned Fructus Lycii, Radix Rehmanniae Preparata, served as, the Radix Paeoniae Alba, the Radix Astragali, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, add 5000mL water, heating decocts 2h, filter, residue adds 5000mL water, and heating decocts 1h, collecting decoction, under reduced pressure, be concentrated to density and be 1.15 clear paste, add 95% ethanol, make to reach 60% containing alcohol amount, hold over night, get supernatant, concentrating under reduced pressure reclaims ethanol, is concentrated into thick paste, add appropriate amount of auxiliary materials, mix homogeneously, adds appropriate refined honey to regulate viscosity, 1000 of pills, every heavy 0.3g, dry, polishing or coating, obtain.
Fructus Lycii 150g, Radix Rehmanniae Preparata 200g, Radix Angelicae Sinensis 150g, Radix Paeoniae Alba 150g, Radix Astragali 60g, Semen Cuscutae 60g, Cortex Phellodendri 40g, Radix Bupleuri 20g, sodium bicarbonate 20g, lemon 40g, lactose is appropriate, essence 5g.
Take above-mentioned Fructus Lycii, Radix Rehmanniae Preparata, served as, the Radix Paeoniae Alba, the Radix Astragali, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, add 5000mL water, heating decocts 2h, filters, residue adds 5000mL water, and heating decocts 1h, and collecting decoction is concentrated to density and is 1.15 clear paste under reduced pressure, add 95% ethanol, make to reach 60%, hold over night containing alcohol amount, get supernatant, concentrating under reduced pressure reclaims ethanol, is concentrated into thick paste, add above-mentioned appropriate amount of auxiliary materials, mix homogeneously, granulates, dry, be pressed into 1000, every heavy 0.3g.
Fructus Lycii 150g, Radix Rehmanniae Preparata 200g, Radix Angelicae Sinensis 150g, Radix Paeoniae Alba 150g, Radix Astragali 60g, Semen Cuscutae 60g, Cortex Phellodendri 40g, Radix Bupleuri 20g, sodium bicarbonate 17g, citric acid 38g, lactose is appropriate, essence 8g.
Take above-mentioned Fructus Lycii, Radix Rehmanniae Preparata, served as, the Radix Paeoniae Alba, the Radix Astragali, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, add 5000mL water, heating decocts 2h, filter, residue adds 5000mL water, and heating decocts 1h, collecting decoction, is concentrated to density and is 1.15 clear paste under reduced pressure, add 95% ethanol, make to reach 60% containing alcohol amount, hold over night, gets supernatant, and concentrating under reduced pressure reclaims ethanol, be concentrated into thick paste, be divided into two equal portions.Portion adds sodium bicarbonate to mix, and makes alkali grain, dry; Another part adds citric acid to mix, and makes acid particles, dry.By two kinds of dried particles mix homogeneously, spray into essence, after sealing certain hour, subpackage, every bag of 3g.
Fructus Lycii 150g, Radix Rehmanniae Preparata 200g, Radix Angelicae Sinensis 150g, Radix Paeoniae Alba 150g, Radix Astragali 60g, Semen Cuscutae 60g, Cortex Phellodendri 40g, Radix Bupleuri 20g, steviosin is appropriate.
Take above-mentioned Fructus Lycii, Radix Rehmanniae Preparata, served as, the Radix Paeoniae Alba, the Radix Astragali, Semen Cuscutae, Cortex Phellodendri, Radix Bupleuri, add 5000mL water, heating decocts 2h, filter, residue adds 5000mL water, and heating decocts 1h, collecting decoction, is concentrated to density and is 1.15 clear paste under reduced pressure, add 95% ethanol, make to reach 60% containing alcohol amount, hold over night, gets supernatant, concentrating under reduced pressure reclaims ethanol, be concentrated into thick paste, add appropriate steviosin, make 300g granule.
The foregoing is only preferred embodiment of the present invention, in order to limit the present invention, within the spirit and principles in the present invention not all, any modification of doing, be equal to replacement, improvement etc., within all should being included in protection scope of the present invention.
Claims (10)
1. a Chinese medicine for the treatment of amblyopia, is characterized in that, comprises the component of following weight portion:
Fructus Lycii 5～20 weight portions, Radix Rehmanniae Preparata 5～25 weight portions, Radix Angelicae Sinensis 5～20 weight portions, the Radix Paeoniae Alba 5～20 weight portions, the Radix Astragali 2～15 weight portions, Semen Cuscutae 2～15 weight portions, Cortex Phellodendri 1～10 weight portion, Radix Bupleuri 1～10 weight portion.
2. a kind of Chinese medicine for the treatment of amblyopia as claimed in claim 1, it is characterized in that, comprise the component of following weight portion: Fructus Lycii 10～20 weight portions, Radix Rehmanniae Preparata 10～20 weight portions, Radix Angelicae Sinensis 10～20 weight portions, the Radix Paeoniae Alba 10～20 weight portions, the Radix Astragali 2～10 weight portions, Semen Cuscutae 2～10 weight portions, Cortex Phellodendri 2～10 weight portions, Radix Bupleuri 2～10 weight portions.
3. a kind of Chinese medicine for the treatment of amblyopia as claimed in claim 2, it is characterized in that, comprise the component of following weight portion: Fructus Lycii 15 weight portions, Radix Rehmanniae Preparata 20 weight portions, Radix Angelicae Sinensis 15 weight portions, the Radix Paeoniae Alba 15 weight portions, the Radix Astragali 6 weight portions, Semen Cuscutae 6 weight portions, Cortex Phellodendri 4 weight portions, Radix Bupleuri 2 weight portions.
4. a kind of Chinese medicine for the treatment of amblyopia as described in claim as arbitrary in claims 1 to 3, is characterized in that: also comprise a kind of or several arbitrarily in diluent, absorbent, wetting agent, binding agent, disintegrating agent, lubricant, suspending agent, flocculating agent, deflocculant, sweeting agent, aromatic, flavoring agent, stabilizing agent or antiseptic.
5. a method of preparing the Chinese medicine of the treatment amblyopia as described in claim as arbitrary in claim 1 to 4, is characterized in that, comprises step:
1) get that the Radix Rehmanniae Preparata of Fructus Lycii, 5～25 amounts part of 5～20 weight portions is heavy, the Radix Angelicae Sinensis of 5～20 weight portions, the Radix Paeoniae Alba of 5～20 weight portions, the Radix Astragali of 2～15 weight portions, the Semen Cuscutae of 2～15 weight portions, the Cortex Phellodendri of 1～10 weight portion, the Radix Bupleuri of 1～10 weight portion;
2) the above-mentioned crude drug taking is added to the water of 5～6 times of weight of described crude drug, at 90～100 ℃, decoct 1.5～2.5h, filter and obtain residue and decocting liquid;
3) above-mentioned residue is added to the water of 5～6 times of weight of described crude drug, at 90～100 ℃, decoct 0.5～1.5h, the decocting liquid that above-mentioned decocting liquid and this decoction are obtained merges;
4) clear paste that is 1～1.3 by the decocting liquid concentrating under reduced pressure after above-mentioned merging to the density with respect to water;
5) to adding mass concentration in above-mentioned clear paste, be 92～98% ethanol, the clear paste alcoholic solution that to obtain containing alcohol amount be 58～62%;
6) by the static 20～24h of above-mentioned clear paste alcoholic solution, get supernatant concentrating under reduced pressure and reclaim ethanol, obtain the Chinese medicine of described treatment amblyopia.
6. a kind of method of preparing the Chinese medicine for the treatment of amblyopia as claimed in claim 5, it is characterized in that: to the water that adds 1～1.2 times of weight of described crude drug in the Chinese medicine of described treatment amblyopia, regulate pH value to 7.1～7.3, stir, standing, filter, subpackage obtains the Chinese medicine oral liquid for the treatment of amblyopia.
7. a kind of method of preparing the Chinese medicine for the treatment of amblyopia as claimed in claim 5, is characterized in that: the traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is granulated, be dried, incapsulate and obtain the capsule of the Chinese medicine of described treatment amblyopia.
8. a kind of method of preparing the Chinese medicine for the treatment of amblyopia as claimed in claim 5, is characterized in that: the traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is made to pill, tablet or the granular preparation of the Chinese medicine of described treatment amblyopia.
9. a kind of method of preparing the Chinese medicine for the treatment of amblyopia as claimed in claim 5, is characterized in that: the traditional Chinese drug inspissation of described treatment amblyopia, to thick paste, is made to the tablet of the Chinese medicine of described treatment amblyopia.
10. a kind of method of preparing the Chinese medicine for the treatment of amblyopia as described in claim as arbitrary in claim 6 to 9, is characterized in that: can also be to adding a kind of or several arbitrarily in diluent, absorbent, wetting agent, binding agent, disintegrating agent, lubricant, suspending agent, flocculating agent, deflocculant, sweeting agent, aromatic, flavoring agent, stabilizing agent or antiseptic in the described Chinese medicine of stating treatment amblyopia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310382306.3A CN103735727A (en) | 2013-08-27 | 2013-08-27 | Traditional Chinese medicine for treating amblyopia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310382306.3A CN103735727A (en) | 2013-08-27 | 2013-08-27 | Traditional Chinese medicine for treating amblyopia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103735727A true CN103735727A (en) | 2014-04-23 |
Family
ID=50492842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310382306.3A Pending CN103735727A (en) | 2013-08-27 | 2013-08-27 | Traditional Chinese medicine for treating amblyopia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735727A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800664A (en) * | 2015-05-21 | 2015-07-29 | 武汉加权科技有限公司 | Medicine for treating amblyopia disease |
| CN106214991A (en) * | 2016-07-08 | 2016-12-14 | 贵州宗智医药科技有限公司 | A kind of Chinese medicine formula for treating amblyopia |
| CN106728677A (en) * | 2016-12-26 | 2017-05-31 | 刘佳 | A kind of Chinese medicine ointment of prophylactic treatment amblyopia |
| CN110960597A (en) * | 2019-12-26 | 2020-04-07 | 浙江大学 | Traditional Chinese medicine granules for relieving asthenopia and treating amblyopia and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1781492A (en) * | 2005-09-29 | 2006-06-07 | 李广中 | Use of zijing in preparing preparation for treating shortsightedness |
| CN1840126A (en) * | 2006-02-06 | 2006-10-04 | 李功淮 | Chinese medicine for treating amblyopia and myopia |
| CN102631558A (en) * | 2012-04-25 | 2012-08-15 | 李敏 | Medicament for treating eye disease and preparation method of medicament |
| CN102836316A (en) * | 2012-09-19 | 2012-12-26 | 张劭茹 | Chinese medicine preparation for treating amblyopia |
-
2013
- 2013-08-27 CN CN201310382306.3A patent/CN103735727A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1781492A (en) * | 2005-09-29 | 2006-06-07 | 李广中 | Use of zijing in preparing preparation for treating shortsightedness |
| CN1840126A (en) * | 2006-02-06 | 2006-10-04 | 李功淮 | Chinese medicine for treating amblyopia and myopia |
| CN102631558A (en) * | 2012-04-25 | 2012-08-15 | 李敏 | Medicament for treating eye disease and preparation method of medicament |
| CN102836316A (en) * | 2012-09-19 | 2012-12-26 | 张劭茹 | Chinese medicine preparation for treating amblyopia |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国卫生部药典委员会编: "《中华人民共和国卫生部药品标准（中药成方制剂）第7册》", 31 December 1998, article "和肝利胆冲剂", pages: 94 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800664A (en) * | 2015-05-21 | 2015-07-29 | 武汉加权科技有限公司 | Medicine for treating amblyopia disease |
| CN106214991A (en) * | 2016-07-08 | 2016-12-14 | 贵州宗智医药科技有限公司 | A kind of Chinese medicine formula for treating amblyopia |
| CN106728677A (en) * | 2016-12-26 | 2017-05-31 | 刘佳 | A kind of Chinese medicine ointment of prophylactic treatment amblyopia |
| CN110960597A (en) * | 2019-12-26 | 2020-04-07 | 浙江大学 | Traditional Chinese medicine granules for relieving asthenopia and treating amblyopia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100571752C (en) | The compound Chinese medicinal preparation of treatment rhinitis | |
| CN103735727A (en) | Traditional Chinese medicine for treating amblyopia and preparation method thereof | |
| CN102441070B (en) | Composition for alleviating eye fatigue | |
| CN102319294A (en) | Double-vanilla preparation and preparation method thereof | |
| CN102078487B (en) | Chinese medicinal preparation for treating vertigo | |
| CN101062356A (en) | Chinese traditional medicine for treating children's enuresis | |
| CN104095982B (en) | A kind of natural plant extracts compound formulation and its production and use | |
| CN102145055B (en) | Sugar-free embolism eliminating oral liquid and preparation method thereof | |
| CN110193061B (en) | Preparation and application of traditional Chinese medicine granules for treating or preventing children influenza virus infection | |
| CN103040974B (en) | Traditional Chinese medicine compound eye drops for preventing cataract and preparation method thereof | |
| CN103055112B (en) | Traditional Chinese medicine compound composition for treating uveitis | |
| CN1056292C (en) | Eyesight granule and its compounding process | |
| CN1966034A (en) | Chinese medicinal formulation for treating infant bed wetting | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN108721353A (en) | A kind of preparation method of Radix Notoginseng oral solution | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN101264312A (en) | Medicaments for treating dizziness | |
| CN101874840A (en) | Total polysaccharide extractive of morinda plants as well as preparation method and application thereof | |
| CN105816599A (en) | Medicinal composition for treating liver and kidney Yang deficiency type narcolepsy | |
| CN1222304C (en) | Medicine for treating turbid vitrious body and its prepn | |
| CN106924191B (en) | Traditional Chinese medicine fine granule and preparation method thereof | |
| CN104873660A (en) | Traditional Chinese medicine for treating children george thrush and preparation method thereof | |
| CN104383465A (en) | Traditional Chinese medicine preparation for treating cataract and preparation method thereof | |
| CN103099945A (en) | Medicinal composition for prevention and treatment of senile cataract and its preparation method | |
| CN108403816A (en) | Pharmaceutical composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140423 |